OncoZenge aims to complete BupiZenge Phase III trial as early as possible in 2027

• OncoZenge aims to complete its Phase III BupiZenge trial as early as possible in 2027, with revised planning within its financial runway.
• Recruitment acceleration efforts include protocol adjustments and closer coordination with trial sites following slower-than-expected enrollment.
• Marketing authorization application preparations and commercial-scale manufacturing in Milan are progressing with European licensee Molteni Farmaceutici.
• Several written, nonbinding licensing offers will be assessed against the potential value of waiting for Phase III results before signing agreements.
• Dental pain development remains a longer-term opportunity to pursue following the Phase III readout in cancer supportive care.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncozenge AB published the original content used to generate this news brief on November 11, 2026, and is solely responsible for the information contained therein.